ABO血型与卵巢癌的相关性研究

doi:10.3760/cma.j.issn.1007-1245.2024.17.011

摘要/Abstract

摘要：

目的　评估ABO血型与卵巢癌的发病、国际妇产科联盟（FIGO）分期及病理分型的关系。方法　收集2012年6月至2023年6月期间在陕西中医药大学第二附属医院确诊且经过初次手术的285例卵巢癌患者临床资料，包括年龄、绝经状态、是否合并恶性腹水，FIGO分期、病理类型、血清癌胚抗原125（CA125）、血型等。选取同期300例卵巢良性肿瘤患者作为对照。回顾性分析ABO血型与卵巢癌发病风险、FIGO分期、病理类型等临床指标之间的关系。采用Kolmogorov-Smirnov检验、F检验、χ²检验、Fisher确切概率法进行统计比较。结果　285例卵巢癌患者中，A、B、O和AB型分别为83例（29.1%）、95例（33.3%）、72例（25.3%）和35例（12.3%）。300例卵巢良性肿瘤患者中，A、B、O和AB型分别为77例（25.7%）、90例（30.0%）、99例（33.0%）、34例（11.3%）。O型血在良性肿瘤中占比最高，B型血在卵巢癌患者中占比最高。不同血型卵巢癌患者的年龄、FIGO分期、病理分型、绝经状态、CA125比较，差异均无统计学意义（均P>0.05）。logistic回归模型显示，B型血是卵巢癌患者发病的风险因素（OR=3.518，95%CI=1.519～8.146，P<0.05）。ABO血型与卵巢癌的FIGO分期、病理类型无明显相关性（均P>0.05）。结论　B型血是卵巢癌患者中较常见的血型，与卵巢癌风险增加有关；ABO血型与卵巢癌的FIGO分期、病理分型无明显关系。

关键词:

卵巢癌, ABO血型, 风险

Abstract:

Objective　To evaluate the relationships of ABO blood types with ovarian cancer onset, International Federation of Gynecology and Obstetrics (FIGO) staging, pathological types. Methods　The relevant clinical data of 285 patients with ovarian cancer who underwent initial surgery and were pathologically diagnosed at Second Hospital, Shaanxi University of Traditional Chinese Medicine were enrolled, including age, menopausal status, presence of malignant ascites, FIGO staging, pathological types, serum carcinoembryonic antigen carcinoembryonic antigen (CA) 125, and blood types. Three hundred patients with benign ovarian tumors during the same period were selected as the controls. The relationships of ABO blood types with ovarian cancer onset risk, FIGO staging, and pathological types were retrospectively analyzed. Kolmogorov Smirnov test, F test, χ² test, and Fisher exact probability were used. Results　Among the 285 patients with ovarian cancer, there were 83 cases (29.1%) of blood type A, 95 cases (33.3%) of type B, 72 cases (25.3%) of type O, and 35 cases (12.3%) of type AB. Among the 300 patients with benign ovarian tumors, there were 77 cases (25.7%) blood type A, 90 cases (30.0%) of type B, 99 cases (33.0%) of type O, and 34 cases (11.3%) of type AB. Type O accounted the highest proportion in the patients with benign ovarian tumors, and type B in the patients with ovarian cancer. There were no statistical differences in age, FIGO staging, pathological types, menopausal status, and CA125 level between the patients of different blood types (all P>0.05). The logistic regression model showed that blood type B was a risk factor for ovarian cancer in the patients (OR=3.518, 95%CI 1.519-8.146, P<0.05). ABO blood types did not correlate with FIGO staging and pathological type of ovarian cancer (both P>0.05). Conclusions　Blood type B is the most common type in patients with ovarian cancer, and is associated with an increased risk of ovarian cancer. ABO blood types do not correlate with FIGO staging and pathological type of ovarian cancer

Key words:

Ovarian cancer, ABO blood types, Risk

杜淑敏孟瑶朱振宁高卫华.

ABO血型与卵巢癌的相关性研究 [J]. 国际医药卫生导报, 2024, 30(17): 2873-2877.

Du Shumin, Meng Yao, Zhu Zhenning, Gao Weihua.

Correlation between ABO blood types and ovarian cancer [J]. International Medicine and Health Guidance News, 2024, 30(17): 2873-2877.

参考文献

[1] Coburn SB, Bray F, Sherman ME, et al. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype[J]. Int J Cancer, 2017,140(11):2451-2460. DOI: 10.1002/ijc.30676.
[2] Léon-Castillo A. Update in the molecular classification of endometrial carcinoma[J]. Int J Gynecol Cancer, 2023,33(3):333-342. DOI: 10.1136/ijgc-2022-003772.
[3] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249. DOI: 10.3322/caac.21660.
[4] Gil-Martin M, Pardo B, Barretina-Ginesta MP. Rare ovarian tumours. Other treatments for ovarian cancer[J]. EJC Suppl, 2020,15:96-103. DOI: 10.1016/j.ejcsup.2019.11.002.
[5] Rummel SK, Ellsworth RE. The role of the histoblood ABO group in cancer[J]. Future Sci OA, 2016,2(2):FSO107. DOI: 10.4155/fsoa-2015-0012.
[6] Nanack JJ, Ferndale L. Factors influencing outcome in patients with perforated peptic ulcer disease at a South African tertiary hospital[J]. S Afr J Surg, 2023,61(4):207-211. DOI: 10.36303/SAJS.4005.
[7] Zhang BL, He N, Huang YB, et al. ABO blood groups and risk of cancer: a systematic review and meta-analysis[J]. Asian Pac J Cancer Prev, 2014,15(11):4643-4650. DOI: 10.7314/apjcp.2014.15.11.4643.
[8] Wang Z, Liu L, Ji J, et al. ABO blood group system and gastric cancer: a case-control study and meta-analysis[J]. Int J Mol Sci, 2012,13(10):13308-13321. DOI: 10.3390/ijms131013308.
[9] Jukic I, Bingulac-Popovic J, Dogic V, et al. Evaluation of ABO blood groups as a risk factor for myocardial infarction[J]. Blood Transfus, 2013,11(3):464-465. DOI: 10.2450/2012.0065-12.
[10] Liu J, Wang D. ABO(H) and Lewis blood group substances and disease treatment[J]. Transfus Med, 2022,32(3):187-192. DOI: 10.1111/tme.12820.
[11] Watchko JF. ABO hemolytic disease of the newborn: a need for clarity and consistency in diagnosis[J]. J Perinatol, 2023,43(2):242-247. DOI: 10.1038/s41372-022-01556-6.
[12] Dogan O. Evaluation of ABO/Rh blood group distributions in papillary thyroid cancer patients[J]. Medicine (Baltimore), 2023,102(32):e34564. DOI: 10.1097/MD.0000000000034564.
[13] Jacoub K, Al-Eisawi Z. ABO blood group and skin cancers[J]. Clin Hemorheol Microcirc, 2022,81(4):359-371. DOI: 10.3233/CH-211290.
[14] Englisch C, Moik F, Nopp S, et al. ABO blood group type and risk of venous thromboembolism in patients with cancer[J]. Blood Adv, 2022,6(24):6274-6281. DOI: 10.1182/bloodadvances.2021006283.
[15] Zhou J, Yang LC, He ZY, et al. Prognostic impact of ABO blood group on the survival in patients with ovarian cancer[J]. J Cancer, 2015,6(10):970-975. DOI: 10.7150/jca.12471.
[16] Zhang W, Xu Q, Zhuang Y, et al. Novel association of soluble intercellular adhesion molecule 1 and soluble P-selectin with the ABO blood group in a Chinese population[J]. Exp Ther Med, 2016,12(2):909-914. DOI: 10.3892/etm.2016.3347.
[17] Sujata S, Verma V, Chandra M. Correlation between ABO blood grouping & allergic rhinosinusitis with and without polyposis & role of TNF-α polymorphism in allergic rhinosinusitis[J]. Indian J Otolaryngol Head Neck Surg, 2023,75 Suppl 1:705-710. DOI: 10.1007/s12070-022-03256-1.
[18] Qin Y, Havulinna AS, Liu Y, et al. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort[J]. Nat Genet, 2022,54(2):134-142. DOI: 10.1038/s41588-021-00991-z.
[19] Gates MA, Wolpin BM, Cramer DW, et al. ABO blood group and incidence of epithelial ovarian cancer[J]. Int J Cancer, 2011,128(2):482-486. DOI: 10.1002/ijc.25339.
[20] Thakur SK, Sompal S, Dinesh Kumar N, et al. Link between human ABO blood groups with diseases influencing blood donors and recipients frequency at RBTC, Delhi, India[J]. Bioinformation, 2023,19(5):576-581. DOI: 10.6026/97320630019576.
[21] Liu F, Li C, Zhu J, et al. ABO blood type and risk of hepatocellular carcinoma: a meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2018,12(9):927-933. DOI: 10.1080/17474124.2018.1500174.
[22] Ergun Y, Esen SA, Bardakci M, et al. Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors[J]. Cancer Biomark, 2022,34(2):329-336. DOI: 10.3233/CBM-210455.
[23] Cui H, Qu Y, Zhang L, et al. Epidemiological and genetic evidence for the relationship between ABO blood group and human cancer[J]. Int J Cancer, 2023,153(2):320-330. DOI: 10.1002/ijc.34533.
[24] Sun W, Wen CP, Lin J, et al. ABO blood types and cancer risk--a cohort study of 339,432 subjects in Taiwan[J]. Cancer Epidemiol, 2015,39(2):150-156. DOI: 10.1016/j.canep.2014.12.006.
[25] Shalaby S, Ronzoni L, Hernandez-Gea V, et al. The genetics of portal hypertension: Recent developments and the road ahead[J]. Liver Int, 2023,43(12):2592-2603. DOI: 10.1111/liv.15732.
[26] Wang C, Zhou J, Wang L, et al. ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women[J]. Cancer Med, 2023,12(6):7498-7507. DOI: 10.1002/cam4.5476.
[27] Zonneveld R, van der Meer-Kapelle L, Sylva M, et al. Severe fetal hemolysis and cholestasis due to high-titer maternal IgG anti-a antibodies[J]. Pediatrics, 2019,143(4):e20182859. DOI: 10.1542/peds.2018-2859.
[28] 王宁宁,朱淑霞,张越华. 铁死亡在神经胶质瘤治疗中的作用[J]. 国际医药卫生导报,2022,28(17):2383-2385. DOI:10.3760/cma.j.issn.1007-1245.2022.17.003.
[29] Means RT. Pure red cell aplasia: the second hundred years[J]. Am J Med Sci, 2023,366(3):160-166. DOI: 10.1016/j.amjms.2023.06.009.
[30] 周仁龙,钟靖,唐丹丹. Kidd血型相关SLC14A1基因在肾透明细胞癌中的表达及临床意义[J]. 临床输血与检验,2024,26(1):92-100. DOI:10.3969/j.issn.1671-2587.2024. 01.015.
[31] Luo Q, Pan M, Feng H, et al. ABO blood group antigen therapy: a potential new strategy against solid tumors[J]. Sci Rep, 2021,11(1):16241. DOI: 10.1038/s41598-021-95794-x.
[32] Bougie DW, Reese SE, Birch RJ, et al. Associations between ABO non-identical platelet transfusions and patient outcomes-a multicenter retrospective analysis[J]. Transfusion, 2023,63(5):960-972. DOI: 10.1111/trf.17319.